Spectrum Pharmaceuticals is a biopharmaceutical company. Co. is acquiring, developing, and commercializing and targeted oncology therapies. Co. has three drugs in development: ROLONTIS, which is a long-acting granulocyte colony-stimulating for chemotherapy-induced neutropenia; Poziotinib, which is an irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, which is an antibody-interferon fusion molecule directed against CD20 that is in development for treating relapsed or refractory non-Hodgkin's lymphoma patients. The SPPI stock yearly return is shown above.
The yearly return on the SPPI stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SPPI annual return calculation with any dividends reinvested as applicable (on ex-dates).
|